Completed PHASE1 INTERVENTIONAL 3-arm NCT01208753

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of GLPG0555 in Healthy Subjects.

Sponsor: Galapagos NV

Conditions Healthy

Interventions GLPG0555 GLPG0555 aqueous placebo

Updated 5 times since 2017 Last updated: Mar 22, 2011 Started: Sep 30, 2010 Primary completion: Nov 30, 2010 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01208753, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Galapagos NV, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galapagos NV

Data source: Galapagos NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Antwerp, Belgium